cbdMD(YCBD.US)

Last Updated 19:00:00 ET
longbridge loading

Analyst Reiterates Buy on cbdMD, Maintains $2 Price Target Amid Solid Revenue Momentum and Strategic Expansion

Tip Ranks·
US
YCBD
-2.60%
US
IBB
+0.10%
US
IXJ
+0.79%
Tip Ranks·
US
YCBD
-2.60%
US
IBB
+0.10%
US
IXJ
+0.79%

Cbdmd Inc Earnings Call: Growth Amid Margin Pressure

Tip Ranks·
US
YCBD
-2.60%
Tip Ranks·
US
YCBD
-2.60%

Full Transcript: cbdMD Q2 2026 Earnings Call

benzinga_article·
US
YCBD
-2.60%
US
FBT
+0.54%
US
SBIO
-1.24%
benzinga_article·
US
YCBD
-2.60%
US
FBT
+0.54%
US
SBIO
-1.24%

cbdMD | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 5.64 M

Earnings Watch·
US
YCBD
-2.60%
Earnings Watch·
US
YCBD
-2.60%

cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum | YCBD Stock News

StockTitan·
US
YCBD
-2.60%
StockTitan·
US
YCBD
-2.60%

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results | YCBD Stock News

StockTitan·
US
YCBD
-2.60%
US
PBE
+0.11%
US
XLV
+1.10%
StockTitan·
US
YCBD
-2.60%
US
PBE
+0.11%
US
XLV
+1.10%

Candy-Coated Costs: How Unvalidated Hemp Gummies Found a Back Door Into Medicare

MorningStar·
US
YCBD
-2.60%
US
CWBHF
+1.54%
MorningStar·
US
YCBD
-2.60%
US
CWBHF
+1.54%
© 2026 Longbridge｜Disclaimer